Why we invested in Huma, insights for better healthcare outcomes

Our healthtech investment team is laser focused on how wearables, sensors, and wellness data are being integrated into clinical environments and producing data to deliver better health outcomes with more convenience and lower cost. Today, healthcare providers and researchers lack a one stop, customizable solution for remote health services. Current solutions are not only condition specific, but often struggle in functionality across the digital biomarker spectrum, and take months to develop.

By gathering real-time health data from patients, Huma creates insights that lead to tangible improvements in diagnosis, treatment, and prevention. The team works alongside scientists, healthcare organizations, pharma professionals, and governments to help provide better care and better research.

We are honored to be an investor in Huma’s Series C funding round, and will continue to champion Dan and his exceptional team as they transform healthcare and research globally. We are particularly excited to see how this capital will be used to further develop Huma’s library of digital biomarkers and predictive algorithms, and expand Huma’s “hospital at home” offering. 

The entire spectrum 

We were drawn to Huma’s mission to power individualized healthcare outside of a traditional hospital. The platform allows clinicians to build condition-specific, customized programs for all involved parties (patient, physicians, management), tracks symptoms and vital signs, flags deterioration, incorporates telemedicine functionality, and integrates with medical devices, wearables, and other connected devices. It provides real-time insights and tangible medical outcomes, while relying on a centralized health data hub which is exemplified by continuous gathering of digital biomarkers. Huma allows its customers to go live with a customized solution in a matter of days, and is building out an ecosystem of proprietary and third party digital biomarkers. 

Huma’s digital phenotyping and biomarker capabilities can provide more objective and continuous pictures of human function in health and disease. This data is advancing predictive health and personalized medicine and is improving the efficiency of clinical trials.

Beyond Covid

At the start of the Covid-19 pandemic, Huma’s team was quick to mobilize, remotely managing patients diagnosed with Covid-19 by tracking symptoms, vital signs, and deterioration, ​via a virtual ward​. As a customizable and easily-deployed solution, health services were also able to take advantage and intervene early, optimize clinical resources, and better manage system capacity.

If we’ve learned anything in the past 18 months, it’s that healthcare will continue to be pushed outside of conventional clinics and further quantified through connected sensors and wearables. In five years, we believe Huma is capable of having a suite of proprietary patented digital biomarkers, and commercial relationships with the leading health systems, research institutions, and pharmaceutical companies to power their relationship with individuals outside of the clinic.